期刊文献+

基于惩罚岭型线性判别对乙酰氨基酚肝毒性代谢组学的研究

Studies on Metabolomics of Liver Toxicity of Acetaminophen based on Penalized Ridge-type Linear Discriminant Analysis
下载PDF
导出
摘要 目的:研究基于惩罚岭型线性判别分析(PRLDA)对乙酰氨基酚(APAP)为肝毒性模型药物,与传统的主成分分析(PCA)比较建立的代谢组学模型的方法学。方法:应用APAP对大鼠肝毒性造模,利用UPLC-MS检测尿液样本,以总离子流色谱为毒性表达变量,运用PRLDA和PCA分别建立APAP肝毒性代谢组学模型。结果:在PRLDA代谢组学模型中,APAP组明显偏离正常组,可以直观看出正常组与模型组的类间差异,具有较强的分类能力;而PCA的分类能力较差。结论:PRLDA代谢组学模型的建立能准确、灵敏地表达药物毒性,并且该方法优于PCA模型。 Objective: To Compare with the principal component analysis (PCA), the methodology of establishing metabolomics model by penalized ridge-type linear discriminant analysis (PRLDA) would be studied based on the liver toxicity of the model drug acetaminophen (APAP). Methods: The rat liver toxicity model was made by using APAP. The rats' urine samples collected were detected by using UPLC-MS. With total ion chromatogram as a variable of ex- pressing toxicity, the metabolomics model on liver toxicity of acetaminophen was established by PRLDA and PCA sep- arately. Results: In the PRLDA metabolomics model, APAP group was deviated from the normal group obviously, and there was a large degree of the difference between the normal group and APAP group. There was a strong classification ability for PRLDA metabolomics model and a poor one for PCA one. Conclusion : The PRLDA metabolomics model could express the drug toxicity accurately and sensitively, and it is better than the PCA model.
出处 《抗感染药学》 2012年第4期264-267,共4页 Anti-infection Pharmacy
基金 国家自然科学基金项目(编号:81001686)
关键词 代谢组学 对乙酰氨基酚 惩罚岭型线性判别 主成分分析 UPLC-MS metabonomics acetaminophen penalized ridge-type linear discriminant analysis principal component analysis UPLC-MS
  • 相关文献

参考文献10

二级参考文献53

  • 1刘仁慧,王宪龄,刘方洲,李佺,黄琦.柴胡黄芩配伍抗大鼠急性酒精性肝损伤作用的实验研究[J].时珍国医国药,2006,17(2):163-164. 被引量:21
  • 2赵剑宇,颜贤忠,彭双清.关木通肾毒性的代谢组学研究[J].中草药,2006,37(5):725-730. 被引量:48
  • 3王占一,戴博,李英哲,廉丽花,南极星.刺五加对他克林所致小鼠急性肝组织损伤的保护作用[J].延边大学医学学报,2007,30(1):31-33. 被引量:4
  • 4戴博,宋妍,王占一,廉丽花,南极星.高山红景天对对乙酰氨基酚所致小鼠急性肝损伤的保护作用[J].时珍国医国药,2007,18(6):1305-1306. 被引量:7
  • 5[2]Bernhard H,Lauterbury 1Early disturbance1 of calcium translocation across the plasma1 membrane in toxic liver injuny J.Hepa tology,1987,7:1179-1184.
  • 6[3]Forrest JA,Clements JA,Prescott LF.Clinical pharmacokinetics of paracetamol.1982,7(2):93-107.
  • 7[4]Doxon M F,Fulker MJ,Walker BE,et al.Serum transam inase levels after experinent paracetamol in duced hepatic necrosis.Gut,1975,116:800.
  • 8[5]Tredger JM,Sm ith HM,DavisM,et al.In vitro interactions of sulfur-containing compounds w ith the hepatic mixed-f unction oxidase system inm ice:effects on paracetamol activation and covalent binding.Toxicol A ppl Pharm acol,1981,59(1):111-124.
  • 9[6]Rosen GM,SingletaryWV,Rauckman EJ,et al.Acetam inophen hepatotoxicity.B iochem Pharm acol,1981,32:2053.
  • 10[8]Shayiq RM.Repeat exposure to increm ental doses of acetam inophen provides protection against acetam inophen-induced lethality in mice:an explanation for high acetam inophen dosage in humans without hepatic injuey.H epatology,1999,29(2):451-463.

共引文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部